Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of all issues and individual articles published by the Journal since 1997.

Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children

Author(s):  Pramann Lance A, Davidow Lawrence W, van Haandel Leon, Funk Ryan S

Issue:  May/Jun 2016 - Volume 20, Number 3
View All Articles in Issue

Page(s):  257-261

Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children Page 1
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children Page 2
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children Page 3
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children Page 4
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children Page 5

Download in electronic PDF format for $75

Abstract:  The purpose of this study was to develop extemporaneously compounded oral liquid formulations of aripiprazole for use in pediatric patients and those patients unable to swallow the solid oral dosage forms. Aripiprazole tablets(30 mg) were ground to a fine powder and suspended at a concentration of 1.0 mg/mL in either a 1:1 blend of Ora-Plus and Ora-Sweet, or 1% methylcellulose and Simple Syrup NF. Five amber, plastic liquid prescription bottles of each formulation were stored at 4°C, and aripiprazole content was measured by ultra-performance liquid chromatography time-of-flight mass spectrometry at 0, 14, 32, 67, and 91 days. Formulations were visually inspected at each time point for color change and precipitation. Forced degradation studies were conducted under oxidizing, acidic, basic, and thermal conditions. Concentrations of aripiprazole in the formulation containing 1:1 Ora-Plus and Ora-Sweet were unchanged over the study period with no signs of degradation over 91 days. In the 1:1 1% methylcellulose and Simple Syrup NF formulation, aripiprazole concentrations were 95% of labeled levels at 67 days, but failed to maintain greater than 90% of labeled levels at 91 days, with an average of only 84% of the labeled content. No apparent physical changes in the formulations were noted over the study period. In the forced degradation studies, loss of aripiprazole was notable under extreme oxidizing and alkaline conditions. Extemporaneously compounded oral suspensions of 1.0 mg/mL aripiprazole in 1:1 Ora-Plus and Ora-Sweet are stable for at least 91 days when stored in amber, plastic prescription bottles at 4°C, whereas suspensions in 1:1 1% methylcellulose and Simple Syrup NF are stable for up to 67 days.

Related Keywords: aripiprazole, oral suspension, formulations, children, infants, neuropsychiatric disorders, psychosis, antipsychotic agent, excipients, stability, forced degradation studies

Related Categories: EXCIPIENTS, FORMULATIONS, MENTAL HEALTH, PEDIATRICS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children
Pramann Lance A
, Davidow Lawrence W, van Haandel Leon, Funk Ryan S
May/Jun 2016
Pg. 257-261

Aripiprazole 1 mg/mL in Oral-Plus:Ora-Sweet (1:1) Oral Suspension
Allen Loyd V Jr
Jul/Aug 2019
Pg. 314

Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312

Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
May/Jun 2016
Pg. 247-249

Aripiprazole 1 mg/mL in Methylcellulose 1% Syrup Oral Suspension
Allen Loyd V Jr
May/Jun 2019
Pg. 230

Pediatric Compounding: Coloring Outside the Lines
Preckshot John
Jan/Feb 2001
Pg. 6-8

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V
, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Sep/Oct 2021
Pg. 431-439

Aripiprazole 10-mg Oral Dissolving Tablets
Allen Loyd V Jr
Jan/Feb 2016
Pg. 49

Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila
, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
Mar/Apr 2017
Pg. 160-163

Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2
Giacoia George P
, Taylor-Zapata Perdita, Mattison Donald
May/Jun 2007
Pg. 220-225

Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Ip Kendice
, Carvalho Maria, Shan Ashley, Banov Daniel
Jul/Aug 2017
Pg. 322-329

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin
, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
May/Jun 2003
Pg. 233-239

Oral Rehydration Salts (World Health Organization/United Nations Children's Fund)
Allen Loyd V Jr
Sep/Oct 2006
Pg. 390

Basics of Sterile Compounding: Excipients Used in Injections
Akers Michael J
Jul/Aug 2017
Pg. 301-308

Temozolomide Stability in Extemporaneously Compounded Oral Suspensions
Trissel Lawrence A
, Zhang Yanping, Koontz Susannah E
Sep/Oct 2006
Pg. 396-399

Women's Oral Health: Is There a Hormonal Link?
Preckshot John
Jan/Feb 2004
Pg. 10-14

Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis
Choo Winnie
Jan/Feb 2016
Pg. 6-10

Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B
, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2020
Pg. 327-336

Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Spennacchio Antonio
, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Jan/Feb 2023
Pg. 72-77

Return to Top